Related Experiment Videos
[KM 2210 therapy for chronic lymphocytic leukemia]
Gan No Rinsho. Japan Journal of Cancer Clinics
|December 1, 1983
Summary
KM 2210 demonstrated effectiveness in treating chronic lymphocytic leukemia (CLL). Two patients achieved complete or partial remission with no observed toxicity, suggesting KM 2210 is a promising therapy for CLL.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy.
- Novel therapeutic agents are needed for CLL treatment.
- KM 2210 is an investigational drug for hematological malignancies.
Observation:
- Two treatment-naive patients with CLL were administered KM 2210 orally at 50 mg/day.
- Treatment durations were 30 days for one patient and 14 days for the other.
- Clinical responses and toxicity were monitored.
Findings:
- One patient achieved a complete remission.
- The second patient achieved a partial remission.
- No adverse events or toxicity were reported in either patient.
Implications:
- KM 2210 shows potential as an effective and well-tolerated treatment for CLL.
- Further clinical trials are warranted to confirm these findings in a larger CLL cohort.
- KM 2210 may represent a new therapeutic option for patients with chronic lymphocytic leukemia.